Effects of aripiprazole on caffeine-induced hyperlocomotion and neural activation in the striatum

Naunyn-Schmiedeberg's Archives of Pharmacology
Luara A BatistaFabricio A Moreira

Abstract

Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors. In addition to its antipsychotic activity, this compound blocks the effects of some psychostimulant drugs. It has not been verified, however, if aripiprazole interferes with the effects of caffeine. Hence, this study tested the hypothesis that aripiprazole prevents caffeine-induced hyperlocomotion and investigated the effects of these drugs on neural activity in the striatum. Male Swiss mice received injections of vehicle or antipsychotic drugs followed by vehicle or caffeine. Locomotion was analyzed in a circular arena and c-Fos protein expression was quantified in the dorsolateral, dorsomedial, and ventrolateral striatum, and in the core and shell regions of nucleus accumbens. Aripiprazole (0.1, 1, and 10 mg/kg) prevented caffeine (10 mg/kg)-induced hyperlocomotion at doses that do not change basal locomotion. Haloperidol (0.01, 0.03, and 0.1 mg/kg) also decreased caffeine-induced hyperlocomotion at all doses, although at the two higher doses, this compound reduced basal locomotion. Immunohistochemistry analysis showed that aripiprazole increases c-Fos protein expression in all regions studied, whereas caffeine did not alter c-Fos protei...Continue Reading

References

Jan 1, 1994·Pharmacology, Biochemistry, and Behavior·B E Garrett, S G Holtzman
Aug 26, 1998·Drug and Alcohol Dependence·J W Daly, B B Fredholm
Nov 5, 1998·The Journal of Comparative Neurology·H J Bennett, K Semba
Feb 21, 2002·Behavioural Brain Research·Robert J CareyErnest Damianopoulos
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David A ShapiroRichard Mailman
Jul 16, 2003·European Journal of Pharmacology·Satoru NakaiTetsuro Kikuchi
Dec 2, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sridhar NatesanShitij Kapur
Mar 21, 2006·Behavioural Brain Research·Vanessa Beijamini, Francisco Silveira Guimarães
Dec 20, 2007·Journal of Neurochemistry·Sergi Ferré
Nov 17, 2009·Current Pharmaceutical Design·Richard B Mailman, Vishakantha Murthy
Feb 16, 2010·Clinical Therapeutics·Emmanuel Stip, Valérie Tourjman
Nov 23, 2010·The International Journal of Neuropsychopharmacology·Sridhar NatesanShitij Kapur
Nov 20, 2012·Basic & Clinical Pharmacology & Toxicology·Thercia G VianaFabricio A Moreira
Dec 7, 2013·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Pedro H GobiraFabrício A Moreira
Dec 19, 2013·The International Journal of Neuropsychopharmacology·Eduardo A V MarinhoRoberto Frussa-Filho
Apr 15, 2014·Psychopharmacology·Sylvain DubroquaPhilipp Singer
Jun 12, 2014·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·X J WenJ Y Hu
Sep 15, 2014·European Journal of Pharmacology·Ana F Almeida-SantosFabricio A Moreira
Feb 6, 2015·Therapeutic Advances in Psychopharmacology·Hannah SteedsJames M Stone
Mar 1, 2015·European Journal of Pharmacology·Fabricio A Moreira, Jeffrey W Dalley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here